Clinical Trial Update: Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating addition of Luveris (recombinant human LH) to FSH from day 8 of ovarian stimulation to reduce total FSH dose and improve ART c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infertility

Drugs mentioned

• Follitropin alfa (folitropin alfa)
• Luveris (lutropin alfa)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Reproductive Techniques, Assisted | Phase 3 | Status: TERMINATED | Results posted: 2012-08-14